BiotechTube

SC291

Phase 1Active
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Hodgkin Lymphoma

Conditions

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

Trial Timeline

May 2, 2023 → Nov 4, 2038

NCT ID
NCT05878184

About SC291

SC291 is a phase 1 stage product being developed by Sana Biotechnology for Non Hodgkin Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT05878184. Target conditions include Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT06294236Phase 1Active
NCT05878184Phase 1Active

Competing Products

20 competing products in Non Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
AFM13AffimedPhase 2
44
VIP152 + BTKiVincerx PharmaPhase 1
25
PLX3397Daiichi SankyoPhase 2
52
YM155 + RituximabAstellas PharmaPhase 2
52
TazemetostatEisaiPhase 2
52
ONTAKEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
TirabrutinibOno PharmaceuticalPhase 1
33
ONO-7018Ono PharmaceuticalPhase 1
33
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
77
ONO-7018 + ONO-7018Ono PharmaceuticalPhase 1
33
R-mabHDI and ABVD + ABVDEli LillyPhase 3
77
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
41
gemcitabineEli LillyPhase 2
52
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
52
LY4152199 - IVEli LillyPhase 1
33
R-mabHD + ABVDEli LillyPhase 2
52
enzastaurin + placeboEli LillyPhase 3
77

Other Products from Sana Biotechnology

SC291Phase 1
28
SC262Phase 1
28
UP421Phase 1
28